RCM
PCVX icon

Regency Capital Management’s Vaxcyte PCVX Stock Holding History

Regency Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-290
Closed -$6K – 163
2021
Q1 		$6K Buy
+290
New +$7.3K 0.01% 128

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Regency Capital Management's PCVX Position: Q2 2021 in Review

Regency Capital Management sold out of Vaxcyte (PCVX) in Q2 2021, closing a stake of 290 shares — an estimated $6K sold.

Regency Capital Management first reported a position in PCVX in Q1 2021 and held it in 1 quarter. The position peaked at $6K in Q1 2021. 75 funds tracked by Wall St. Rank hold PCVX as of Q2 2021.

  • Regency Capital Management reported no remaining Vaxcyte position as of Q2 2021 after selling out during the quarter.
  • Regency Capital Management sold 290 Vaxcyte shares in Q2 2021, an estimated $6K.
  • Regency Capital Management first reported a position in Vaxcyte in Q1 2021 and held it in 1 quarter.
  • Regency Capital Management's Vaxcyte position peaked at $6K in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2021.

Based on Regency Capital Management's 13F filing for Q2 2021, filed 7 Jul 2021.